Highlighting CAR T Cell Options for Relapsed/Refractory DLBCL

March 14, 2019
David Miklos, MD

David Miklos, MD, discusses his advice for community oncologists treating patients with diffuse large B-cell lymphoma.

David Miklos, MD, associate professor of medicine at Stanford University, discusses his advice for community oncologists treating patients with diffuse large B-cell lymphoma (DLBCL).

Miklos says it is important to know that chimeric antigen receptor (CAR) T cells are effective and available for patients with relapsed/refractory DLBCL.